Condition: Neuroendocrine Tumors · NET · Pancreatic Neuroendocrine Tumor · Sponsor: Aadi Bioscience, Inc.
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors
This description comes directly from the study's public registry record.
Aadi Bioscience Medical Information · 1-888-246-2234 · MedInfo@aadibio.com
Always discuss trial participation with your own doctor first.
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Texas Oncology | Dallas, Texas, United States | Recruiting |
| Medical College of Wisconsin Cancer Center | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05997056